NEW YORK – Dante Labs announced Tuesday its Immensa software received CE-IVD marking for the interpretation of whole-genome sequencing data in a clinical setting at scale.
The software generates personalized reports for pharmacogenomics, rare diseases, predisposition to common diseases, and nutrigenomics, and integrates guidelines from the American College of Medical Genetics, the company said.
It was built using more than 150,000 genomic reports generated by Dante Labs and integrated user feedback. The software takes 30 seconds to generate a report and can scale with demand, the firm said.
Dante Labs CEO Andrea Riposati said in a statement the software will be available commercially to clinics and hospitals in countries accepting the CE mark “in a few weeks.”